Study on PK-PD characteristics of ginsenoside Rg1 and Rb1 in rats with myocardial ischemia following intravenous administration of Shengmai injection

Zhongguo Zhongyao Zazhi

Volumn 39, Issue 7, 2014, Pages 1300-1305

  Zhan, Shu Yu ^a   Shao, Qing ^a   Li, Zheng ^b   Wang, Yi ^a   Fan, Xiao Hui ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Nitric oxide; Shengmai injection; The combined pharmacokinetics pharmacodynamics (PK PD)

Indexed keywords

CHINESE DRUG; GINSENOSIDE RB 1; GINSENOSIDE RG 1; ISOPRENALINE; NITRIC OXIDE; NITRIC OXIDE 2; NITRIC OXIDE 3; SHENGMAI; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; HEART MUSCLE ISCHEMIA; NONHUMAN; PHARMACODYNAMICS; RAT; THEORY OF EFFECT COMPARTMENT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; GINSENOSIDES; HUMANS; MALE; MYOCARDIAL ISCHEMIA; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84902175949     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20140729     Document Type: Article

References (25)

1. Abdel-Rahman S M, Kauffman R E. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response[J]. Annu Rev Pharmacol Toxicol, 2004, 44: 111.
2. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives[J]. J Pharmacokinet Pharmacodyn, 2006, 33(3): 227.
3. 2009, 28(5): 86.
4. 2009, 40(11): 1830.
5. 2004, 39(5): 366.
6. Chen J, Yao Y, Chen H, et al. Shengmai(a traditional Chinese herbal medicine) for heart failure[J]. Cochrane Database Syst Rev, 2012, 11: CD005052.
7. 2009, 31(4): 653.
8. 2010, 28(11): 2310.
9. 2011, 20(9): 803.
10. Sheiner L B, Stanski D R, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine[J]. Clin Pharmacol Ther, 1979, 25(3): 358.
11. Holford N H, Sheiner L B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models[J]. Clin Pharmacokinet, 1981, 6(6): 429.
12. 2012.
13. Zhan S Y, Shao Q, Liu L, et al. A simple and accurate method to determine nitrite and nitrate in serum based on high-performance liquid chromatography with fluorescence detection[J]. Biomed Chromatogr, 2013, 27(11): 1547.
14. 1 from Panax notoginseng in rats[J]. J Ethnopharmacol, 2003, 84(2/3): 187.
15. 1 and ginsenoside Rb, of Panax notoginseng saponins[J]. Acta Pharm Sin, 2007, 42(8): 849.
16. Liu H, Yang J, Du F, et al. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats[J]. Drug Metab Dispos, 2009, 37(12): 2290.
17. Sheiner L B, Steimer J L. Pharmacokinetic/pharmacodynamic modeling in drug development[J]. Annu Rev Pharmacol Toxicol, 2000, 40: 67.
18. Derendorf H, Lesko L J, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development[J]. J Clin Pharmacol, 2000, 40(12 Pt 2): 1399.
19. 1 leading to nitric oxide production in endothelial cells[J]. FEBS Lett, 2006, 580(13): 3211.
20. 1 in human aortic endothelial cells: a possible involvement of androgen receptor[J]. Biochem Biophysi Res Communic, 2007, 353(3): 764.
21. Leung K W, Leung F P, Mak N K, et al. Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells[J]. Br J Pharmacol, 2009, 156(4): 626.
22. Pan C, Huo Y, An X, et al. Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation[J]. Vascul Pharmacol, 2012, 56(3/4): 150.
23. Chu K M, Hu O Y, Shieh S M. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects[J]. Drug Metab Dispos, 1999, 27(6): 701.
24. Liu X Y, Wang B J, Yuan G Y, et al. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic(PK-PD) modeling of carvedilol[J]. Acta Pharm Sin, 2009, 44(4): 406.
25. 2005, 21(4): 464.